Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma

Oncology

Volumn 81, Issue 5-6, 2012, Pages 281-290

  Yamashita, Tatsuya ^a   Arai, Kuniaki ^a   Sunagozaka, Hajime ^a   Ueda, Teruyuki ^a   Terashima, Takeshi ^a   Yamashita, Taro ^a   Mizukoshi, Eishiro ^a   Sakai, Akito ^a   Nakamoto, Yasunari ^b   Honda, Masao ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; Hepatic arterial infusion; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER PROGNOSIS; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; HEPATIC ARTERY; HEPATIC ARTERY INFUSION; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 82355184589     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000334439     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16. (Pubitemid 39423365)
3. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-1380. (Pubitemid 39457763)
4. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M: Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-685.
5. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M: Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691. (Pubitemid 47054774)
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
8. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595. (Pubitemid 34810185)
9. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-1991.
10. Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Principato R, Martz K, Zeiger LS: Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002; 20: 613-625. (Pubitemid 37210031)
11. Kaneko S, Urabe T, Kobayashi K: Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002; 62(suppl 1):69-73. (Pubitemid 34702023)
12. Lin CP, Yu HC, Cheng JS, Lai KH, Lo GH, Hsu PI, Lin CK, Chen HH, Lo CC, Liang HL, Tseng HH: Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004; 67: 602-610.
13. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997. (Pubitemid 43673215)
14. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Tanikawa K: Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999; 6: 587-591.
15. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
16. Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, Sata M: Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003; 181: 1327-1334. (Pubitemid 37296411)
17. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M: Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891-1897. (Pubitemid 36750863)
18. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557-564. (Pubitemid 43079999)
19. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK: Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 1122-1125. (Pubitemid 29224804)
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
21. Uka K, Aikata H, Takaki S, Kawaoka T, Saneto H, Miki D, Takahashi S, Toyota N, Ito K, Chayama K: Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. World J Gastroenterol 2008; 14: 2602-2608. (Pubitemid 352037757)
22. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516-523. (Pubitemid 36975769)
23. Eguchi H, Nagano H, Yamamoto H, Miyamoto A, Kondo M, Dono K, Nakamori S, Umeshita K, Sakon M, Monden M: Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with upregulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000; 6: 2881-2890. (Pubitemid 30482131)
24. Takaki-Hamabe S, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, Sakaida I: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009; 39: 223-230.
25. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC: Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 2009; 44: 1477-1486.
26. Moriyama M, Hoshida Y, Kato N, Otsuka M, Yoshida H, Kawabe T, Omata M: Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. Int J Oncol 2004; 25: 1279-1287.
27. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H: Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78(suppl 1):148-153.
28. Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, Saito N, Matsukawa M, Shirasaka T, Kurihara M: Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620-2628. (Pubitemid 29437350)
29. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S: Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 2004; 24: 807-813.
30. Hamada A, Yamakado K, Nakatsuka A, Takaki H, Akeboshi M, Takeda K: Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol 2004; 15: 835-841. (Pubitemid 39063223)
31. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, Tajima K, Yokoyama Y, Takami T, Omori K, Kawaguchi K, Tsuchiya M, Terai S, Sakaida I, Okita K: Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-78. (Pubitemid 40796335)
32. Buendia MA: Hepatitis B viruses and cancerogenesis. Biomed Pharmacother 1998; 52: 34-43. (Pubitemid 28138805)
33. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C, Pizzigallo E, Conti P, Vecchiet J: Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006; 36: 144-150.
34. Robinson WS: Molecular events in the pathogenesis of hepadnavirus- associated hepatocellular carcinoma. Annu Rev Med 1994; 45: 297-323. (Pubitemid 24158164)
35. Someya T, Ikeda K, Saitoh S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H: Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006; 41: 1206-1213. (Pubitemid 46487211)
36. Cheong JY, Lee KM, Cho SW, Won JH, Kim JK, Wang HJ, Hahm KB, Kim JH: Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2005; 32: 127-133. (Pubitemid 40945773)